Literature DB >> 8773577

Ex vivo model of leukocyte migration into herpes simplex virus-infected mouse corneas.

W Chen1, Q Tang, R L Hendricks.   

Abstract

We are investigating neutrophilic infiltration into herpes simplex virus type 1 (HSV-1)-infected mouse corneas. Using a novel ex vivo corneal migration assay, we demonstrated two waves of neutrophil chemotaxis in HSV-1-infected corneas. An early chemotactic gradient developed within 48 h in concert with the appearance of HSV-1 epithelial lesions, peaked by 4 days post-infection (p.i.), and degraded by 6-8 days p.i.. A second chemotactic gradient appeared 10 days after infection, just before the initiation of chronic inflammation. The gradient was maintained in corneas that developed inflammation but rapidly degraded in corneas that failed to develop inflammation. The early chemotactic gradient was established in the absence of T lymphocytes, but the second chemotactic gradient was virtually abrogated by T cell depletion. We conclude that HSV-1 infection induces two temporally separated neutrophil chemotactic gradients in the mouse cornea: an early, transient, T cell-independent gradient; and a later, chronic, T cell-dependent gradient.

Entities:  

Mesh:

Year:  1996        PMID: 8773577     DOI: 10.1002/jlb.60.2.167

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  11 in total

1.  MRP8/14 enhances corneal susceptibility to Pseudomonas aeruginosa Infection by amplifying inflammatory responses.

Authors:  Qiuchan Deng; Mingxia Sun; Kun Yang; Min Zhu; Kang Chen; Jin Yuan; Minhao Wu; Xi Huang
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-01       Impact factor: 4.799

2.  Kinetics of immune cell infiltration in vaccinia virus keratitis.

Authors:  Sharon Altmann; Megan Toomey; Brittany Nesbit; Kim McIntyre; Jill Covert; Richard Redd Dubielzig; Gary Leatherberry; Elizabeth Adkins; Christopher J Murphy; Curtis R Brandt
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-04-07       Impact factor: 4.799

3.  Both CD8+ and CD4+ T Cells Contribute to Corneal Clouding and Viral Clearance following Vaccinia Virus Infection in C57BL/6 Mice.

Authors:  I V Larsen; H Clausius; A W Kolb; C R Brandt
Journal:  J Virol       Date:  2016-06-24       Impact factor: 5.103

Review 4.  Immunopathogenesis of herpetic ocular disease.

Authors:  J Thomas; B T Rouse
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

5.  Tegument-specific, virus-reactive CD4 T cells localize to the cornea in herpes simplex virus interstitial keratitis in humans.

Authors:  D M Koelle; S N Reymond; H Chen; W W Kwok; C McClurkan; T Gyaltsong; E W Petersdorf; W Rotkis; A R Talley; D A Harrison
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

6.  CD154 signaling regulates the Th1 response to herpes simplex virus-1 and inflammation in infected corneas.

Authors:  Min Xu; Andrew J Lepisto; Robert L Hendricks
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

Review 7.  Herpes keratitis.

Authors:  A M Rowe; A J St Leger; S Jeon; D K Dhaliwal; J E Knickelbein; R L Hendricks
Journal:  Prog Retin Eye Res       Date:  2012-08-27       Impact factor: 21.198

8.  Resident Corneal Cells Communicate with Neutrophils Leading to the Production of IP-10 during the Primary Inflammatory Response to HSV-1 Infection.

Authors:  S J Molesworth-Kenyon; N Popham; A Milam; J E Oakes; R N Lausch
Journal:  Int J Inflam       Date:  2012-03-15

9.  Infected cell protein (ICP)47 enhances herpes simplex virus neurovirulence by blocking the CD8+ T cell response.

Authors:  K Goldsmith; W Chen; D C Johnson; R L Hendricks
Journal:  J Exp Med       Date:  1998-02-02       Impact factor: 14.307

10.  Murine Corneal Inflammation and Nerve Damage After Infection With HSV-1 Are Promoted by HVEM and Ameliorated by Immune-Modifying Nanoparticle Therapy.

Authors:  Rebecca G Edwards; Sarah J Kopp; Igal Ifergan; Jr-Wen Shui; Mitchell Kronenberg; Stephen D Miller; Richard Longnecker
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-01-01       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.